论文部分内容阅读
最新研究证实长效胰高血糖素类肽-1(GLP-1)衍生物 liraglutide(LG)治疗2型糖尿病可改善患者的血糖控制,且不增加体重。来自于丹麦 Frederiksberg 皇家兽医和农业大学的 Arne Astrup 教授及其同事报道说,使用胰岛素、磺脲类和噻唑烷二酮类治疗亦可改善患者的血糖控制,但体重有所增加。在33例血糖控制相当好的2型糖尿病患者中,研究人员对 LG 影响血糖控制、身体组成和24小时能耗的作用进行了分析;受试者连续8周被随机指定或1次/天自己皮下注射0.6mg的 LG(n=21)或安慰剂(n=12)。与安慰剂组相比,治疗组患者的空腹血糖降低2.2mmol/L,HbA1c 降低0.8%,且不增加体重。事实上,研究还发现脂肪总量有减少的倾向,而 LG治疗者的肌肉组织量有增加的趋势;但这些变化无显著意义。该结果提示,如果剂量更大些,时间更
Recent studies confirm that liraglutide (LG), a long-acting glucagon-like peptide-1 (GLP-1) derivative, can improve glycemic control in patients with type 2 diabetes without increasing body weight. Professor Arne Astrup from Royal Veterinary and Agricultural University Frederiksberg, Denmark, and colleagues report that treatment with insulin, sulfonylureas and thiazolidinediones improves glycemic control but increases body weight. In 33 patients with well-controlled glycemic control of type 2 diabetes, the researchers analyzed the effects of LG on glycemic control, body composition, and 24-hour energy use; subjects were randomly assigned or treated once a day for 8 weeks Subcutaneous injection of 0.6 mg of LG (n = 21) or placebo (n = 12). Compared with placebo, patients in the treatment group had a fasting glucose decrease of 2.2 mmol / L, a decrease of 0.8% in HbA1c, and no increase in body weight. In fact, the study also found that there was a tendency to reduce the total amount of fat, while LG treated patients tended to have increased muscle mass; however, these changes were not significant. The results suggest that if the dose is larger, the time is more